NCT07109154 DeniLA: Comprehensive Demographics and Clinical Profile of NSCLC Patients: Analyzing Guideline-Concordant Care in First-line Treatment Patterns
| NCT ID | NCT07109154 |
| Status | Recruiting |
| Phase | — |
| Sponsor | AstraZeneca |
| Condition | Lung Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-11-25 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2025-11-25 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, observational, multicenter study, in which clinical and demographic data will be extracted from medical records. Convenience sample, with an estimated inclusion of 200 patients treated in seven participating centers. Eligible tumors for this project will be from patients with advanced (unresectable or metastatic) non-small cell lung carcinoma, who will start first-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026). Patients must be over 18 years old and data must be available in electronic medical records. Medical records will be assessed to confirm patients' eligibility. Patients with localized disease amenable to local treatment, non-epithelial histology, small cell carcinoma and neuroendocrine tumor will not be eligible. A survey will be designed targeting thoracic and generalist medical oncologists, aiming to understand the factors guiding the choice of first-line treatment regimens and to compare these insights with real-world data. The survey will be directed to Brazil, with an estimated of 200 filled files.
Eligibility Criteria
Inclusion Criteria: * Advanced (unresectable or metastatic) non-small cell lung carcinoma * First-line oncological treatment in one of the participating centers between 2025 and 2026 (between January 2025 and January 2026) * \> 18 years old * Data available in electronic medical records. Exclusion Criteria: * Localized disease amenable to local treatment * Non-epithelial histology * Small cell carcinoma * Neuroendocrine tumor * Patients with unresectable NSCLC who underwent treatment with the PACIFIC protocol and are being followed up.
Contact & Investigator
Clarissa Baldotto
PRINCIPAL INVESTIGATOR
Instituto D'Or de Pesquisa e Ensino
Frequently Asked Questions
Who can join the NCT07109154 clinical trial?
This trial is open to participants of all sexes, studying Lung Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07109154 currently recruiting?
Yes, NCT07109154 is actively recruiting participants. Contact the research team at information.center@astrazeneca.com for enrollment information.
Where is the NCT07109154 trial being conducted?
This trial is being conducted at Recife, Brazil, Rio de Janeiro, Brazil, Rio de Janeiro, Brazil, Salvador, Brazil and 3 additional locations.
Who is sponsoring the NCT07109154 clinical trial?
NCT07109154 is sponsored by AstraZeneca. The principal investigator is Clarissa Baldotto at Instituto D'Or de Pesquisa e Ensino. The trial plans to enroll 200 participants.